{"title":"非医用氧化亚氮青少年使用者的精神和神经认知不良事件。","authors":"Margot Lestienne, Alexandra Macgregor, Laurie Surig, Hélène Donnadieu, Etienne Mondesert, Céline Eiden, Hélène Peyrière","doi":"10.1097/JCP.0000000000002070","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose/background: </strong>For several years, an increase in the nonmedical use of nitrous oxide (N 2 O) has been observed in France, among adolescents and young adults, sometimes associated with severe adverse events.</p><p><strong>Methods/procedures: </strong>Analysis of spontaneous reports (SRs) concerning neuropsychiatric adverse events in N 2 O users, received by the Montpellier addictovigilance centre between 2022 and June 2024, and discussion of the underlying pharmacological mechanisms.</p><p><strong>Findings/results: </strong>Nineteen severe SRs were analysed, mainly in men (73.6%, mean age: 23.1 ± 7.3 y) and concerned psychiatric disorders (n = 11), neurocognitive disorders (n = 2), or both (n = 6). Associated consumptions were mainly cannabis (38.9%). Reported symptoms were psychiatric (mainly behavioural disorders, n = 14; delusion, n = 10), and/or neurocognitive (mainly memory disorders, n = 5; spatiotemporal disorientation, n = 3; cognitive slowing, n = 3).Vitamin B12 dosage was performed in 11 cases (<145 pmol/l: 4 cases, mean: 245.4 ± 118 pmol/l), homocysteine in 10 cases (>15 μmol/l: all cases, mean: 80.3 ± 54 μmol/l), methylmalonic acid in 6 cases (>0.5 μmol/l: 4 cases, mean: 1.2 ± 1.7 μmol/l), and vitamin B9 (<8.83 nmol/l: 2 cases, mean: 16.2 ± 9.7 nmol/l). When performed (n = 8), magnetic resonance imaging revealed white matter abnormalities with punctiform hyperintensities in 6 cases. Twelve have received long-term antipsychotic medication, and 9 vitamin supplementation.N 2 O combines potentially neurotoxic mechanisms: psychoactive (glutamatergic receptor antagonist, opioid/GABAergic effects), biochemical (disruption of vitamin B12 metabolism) and anoxic.</p><p><strong>Implications/conclusions: </strong>These observations highlight the importance and uniqueness of N 2 O-induced neuropsychiatric disorders. N 2 O abuse should be considered in any young patient with psychiatric disorders of unknown origin, particularly when associated with atypical cognitive disorders.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Psychiatric and Neurocognitive Adverse Events in Young Users of Nonmedical Nitrous Oxide.\",\"authors\":\"Margot Lestienne, Alexandra Macgregor, Laurie Surig, Hélène Donnadieu, Etienne Mondesert, Céline Eiden, Hélène Peyrière\",\"doi\":\"10.1097/JCP.0000000000002070\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose/background: </strong>For several years, an increase in the nonmedical use of nitrous oxide (N 2 O) has been observed in France, among adolescents and young adults, sometimes associated with severe adverse events.</p><p><strong>Methods/procedures: </strong>Analysis of spontaneous reports (SRs) concerning neuropsychiatric adverse events in N 2 O users, received by the Montpellier addictovigilance centre between 2022 and June 2024, and discussion of the underlying pharmacological mechanisms.</p><p><strong>Findings/results: </strong>Nineteen severe SRs were analysed, mainly in men (73.6%, mean age: 23.1 ± 7.3 y) and concerned psychiatric disorders (n = 11), neurocognitive disorders (n = 2), or both (n = 6). Associated consumptions were mainly cannabis (38.9%). Reported symptoms were psychiatric (mainly behavioural disorders, n = 14; delusion, n = 10), and/or neurocognitive (mainly memory disorders, n = 5; spatiotemporal disorientation, n = 3; cognitive slowing, n = 3).Vitamin B12 dosage was performed in 11 cases (<145 pmol/l: 4 cases, mean: 245.4 ± 118 pmol/l), homocysteine in 10 cases (>15 μmol/l: all cases, mean: 80.3 ± 54 μmol/l), methylmalonic acid in 6 cases (>0.5 μmol/l: 4 cases, mean: 1.2 ± 1.7 μmol/l), and vitamin B9 (<8.83 nmol/l: 2 cases, mean: 16.2 ± 9.7 nmol/l). When performed (n = 8), magnetic resonance imaging revealed white matter abnormalities with punctiform hyperintensities in 6 cases. Twelve have received long-term antipsychotic medication, and 9 vitamin supplementation.N 2 O combines potentially neurotoxic mechanisms: psychoactive (glutamatergic receptor antagonist, opioid/GABAergic effects), biochemical (disruption of vitamin B12 metabolism) and anoxic.</p><p><strong>Implications/conclusions: </strong>These observations highlight the importance and uniqueness of N 2 O-induced neuropsychiatric disorders. N 2 O abuse should be considered in any young patient with psychiatric disorders of unknown origin, particularly when associated with atypical cognitive disorders.</p>\",\"PeriodicalId\":15455,\"journal\":{\"name\":\"Journal of Clinical Psychopharmacology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-08-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Psychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/JCP.0000000000002070\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/JCP.0000000000002070","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Psychiatric and Neurocognitive Adverse Events in Young Users of Nonmedical Nitrous Oxide.
Purpose/background: For several years, an increase in the nonmedical use of nitrous oxide (N 2 O) has been observed in France, among adolescents and young adults, sometimes associated with severe adverse events.
Methods/procedures: Analysis of spontaneous reports (SRs) concerning neuropsychiatric adverse events in N 2 O users, received by the Montpellier addictovigilance centre between 2022 and June 2024, and discussion of the underlying pharmacological mechanisms.
Findings/results: Nineteen severe SRs were analysed, mainly in men (73.6%, mean age: 23.1 ± 7.3 y) and concerned psychiatric disorders (n = 11), neurocognitive disorders (n = 2), or both (n = 6). Associated consumptions were mainly cannabis (38.9%). Reported symptoms were psychiatric (mainly behavioural disorders, n = 14; delusion, n = 10), and/or neurocognitive (mainly memory disorders, n = 5; spatiotemporal disorientation, n = 3; cognitive slowing, n = 3).Vitamin B12 dosage was performed in 11 cases (<145 pmol/l: 4 cases, mean: 245.4 ± 118 pmol/l), homocysteine in 10 cases (>15 μmol/l: all cases, mean: 80.3 ± 54 μmol/l), methylmalonic acid in 6 cases (>0.5 μmol/l: 4 cases, mean: 1.2 ± 1.7 μmol/l), and vitamin B9 (<8.83 nmol/l: 2 cases, mean: 16.2 ± 9.7 nmol/l). When performed (n = 8), magnetic resonance imaging revealed white matter abnormalities with punctiform hyperintensities in 6 cases. Twelve have received long-term antipsychotic medication, and 9 vitamin supplementation.N 2 O combines potentially neurotoxic mechanisms: psychoactive (glutamatergic receptor antagonist, opioid/GABAergic effects), biochemical (disruption of vitamin B12 metabolism) and anoxic.
Implications/conclusions: These observations highlight the importance and uniqueness of N 2 O-induced neuropsychiatric disorders. N 2 O abuse should be considered in any young patient with psychiatric disorders of unknown origin, particularly when associated with atypical cognitive disorders.
期刊介绍:
Journal of Clinical Psychopharmacology, a leading publication in psychopharmacology, offers a wide range of articles reporting on clinical trials and studies, side effects, drug interactions, overdose management, pharmacogenetics, pharmacokinetics, and psychiatric effects of non-psychiatric drugs. The journal keeps clinician-scientists and trainees up-to-date on the latest clinical developments in psychopharmacologic agents, presenting the extensive coverage needed to keep up with every development in this fast-growing field.